CurrentEmblemHealthPolicy N/A

Erythropoiesis‑Stimulating Agents — Epoetin Alfa Products (Medical Utilization Management)

Medicare Advantage medical policy governing prior authorization and coverage criteria for epoetin alfa products (Epogen, Procrit, Retacrit) for anemia indications including CKD (on and not on dialysis), chemotherapy‑related anemia, HIV/zidovudine‑related anemia, perioperative use to reduce RBC transfusions, and select hematologic disorders; affects providers seeking medical‑benefit coverage under EmblemHealth Medicare Advantage.

Policy Summary

PayerEmblemHealth

PolicyErythropoiesis‑Stimulating Agents — Epoetin Alfa Products (Medical Utilization Management)

Policy CodePolicy N/A

Change TypeClinical revisions and dosing/threshold updates

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization with documentation of indication, hemoglobin level, iron status or current iron therapy, and dosing within allowed monthly units when seeking coverage for epoetin alfa.

SourceLink

POLICY UPDATE CHANGES

Anemia in Patients with Cancer due to Cancer Chemotherapy: initial therapy approval duration changed to 6 months and added requirement that patient meet one of iron status conditions (currently receiving iron therapy OR has adequate stores per prescriber).

Anemia in a Patient with Chronic Kidney Disease not on Dialysis: dosing changed to approve if doses are equivalent to < 60,000 units total per month.

Hemoglobin threshold for patients currently receiving an ESA in CKD not on dialysis changed from 11.5 to <12.0 g/dL and age-based delineation removed.

This policy incorporates Medicare coverage guidance as set forth in National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) and companion articles; cited lists of HCPCS and ICD-10 codes are for reference only and not by themselves sufficient for coverage.

Non-clinical note excluding states in Palmetto GBA jurisdictions J-J and J-M (including NC) from this policy.

3 yrs

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Indications

CKD on dialysis (FDA‑approved)

Covered when ALL of the following are met for CKD on dialysis

CKD on dialysis: Anemia in patients with chronic kidney disease who are on dialysis.Approve for 3 years

FDA‑approved indication

CKD not on dialysis

Covered when ALL of the following are met for CKD not on dialysis

CKD not on dialysis - Initial Therapy: Patient ≥18 years with hemoglobin ≤10.0 g/dL; AND patient is currently receiving iron therapy OR has adequate iron stores per prescriber.Approve for 1 year

Use lowest dose sufficient to reduce transfusions; dosing equivalent < 60,000 units total per month

CKD not on dialysis - Ongoing ESA: Patient currently receiving an ESA; hemoglobin <12.0 g/dL; AND patient is currently receiving iron therapy OR has adequate iron stores per prescriber.Approve for 1 year

Dosing limits apply (approved monthly dosing equivalent < 60,000 units)

Anemia with HIV receiving zidovudine

Covered when ALL of the following are met for HIV patients on zidovudine

HIV/zidovudine - Initial Therapy: Patient has hemoglobin ≤10.0 g/dL; AND is currently receiving zidovudine; AND serum erythropoietin <500 mU/mL; AND patient is currently receiving iron therapy OR has adequate iron stores per prescriber.Approve for 1 year

Per‑dose and frequency limits apply (each dose <300–400 Units/kg and no more frequently than 3×/week depending on age)

HIV/zidovudine - Ongoing ESA: Patient currently receiving an ESA; currently receiving zidovudine; hemoglobin <12.0 g/dL; AND patient is currently receiving iron therapy OR has adequate iron stores per prescriber.Approve for 1 year

Per‑dose and frequency limits apply

Anemia due to cancer chemotherapy

Covered when ALL of the following are met for chemotherapy‑related anemia

Cancer chemotherapy anemia - Initial Therapy: Patient has hemoglobin ≤10.0 g/dL (or hematocrit 30%); AND patient is currently receiving myelosuppressive chemotherapy that is non‑curative per prescriber; AND patient is currently receiving iron therapy OR has adequate iron stores per prescriber.Approve for 6 months (initial)

Dose limits: examples include each dose <300 Units/kg and frequency restrictions OR per‑dose maximums (e.g., <60,000 Units with no more than once weekly); documentation of chemotherapy status and iron therapy required

Cancer chemotherapy anemia - Ongoing ESA: Patient currently receiving an ESA; hemoglobin <12.0 g/dL (or hematocrit 30%); patient currently receiving myelosuppressive chemotherapy considered non‑curative; AND patient has adequate iron or is on iron therapy.Approve for 6 months

Dosing constraints apply; continuation requires documentation of response and iron status

Reduction of allogeneic RBC transfusions for elective surgery

Covered when ALL of the following are met for perioperative reduction of RBC transfusions

Perioperative RBC transfusion reduction: Elective, noncardiac/nonvascular surgery; hemoglobin <13.0 g/dL; patient not willing/able to donate autologous blood; AND patient is on iron therapy OR has adequate iron stores per prescriber.Approve for 1 month

Dosing limits include per‑dose Units/kg limits and total dose caps (examples: each dose <300 Units/kg with total doses <15 OR each dose <600 Units/kg with total doses <4)

MDS and myelofibrosis

Covered when ALL of the following are met for select hematologic disorders

Myelodysplastic Syndromes (MDS): Patient ≥18 years with hemoglobin <10.0 g/dL (initial) OR currently receiving ESA with hemoglobin <12.0 g/dL; AND serum erythropoietin <500 mU/mL for initial therapy or adequate iron / iron therapy per prescriber.Approve for 1 year

Dose: each dose <60,000 Units and no more frequently than 2×/week

Myelofibrosis: Initial: patient with hemoglobin <10.0 g/dL OR serum erythropoietin <500 mU/mL; AND patient is currently receiving iron therapy OR has adequate iron stores. Response (Hb ≥10 g/dL or increase ≥2 g/dL) required for continuation in some scenarios.Initial approve 3 months; ongoing up to 1 year if criteria met

Dose: each dose <60,000 Units and no more frequently than once every 2 weeks

Revised coverage criteria highlights

Selected coverage criteria and limits as revised in history:

Chemotherapy-induced anemia initial therapy: Initial therapy approval duration is 6 months; patient must be on myelosuppressive chemotherapy or receiving non‑curative treatment per prescriber; iron status requirement: patient is currently receiving iron therapy OR has adequate iron stores as documented by prescriber.6 months

Recorded in policy history revisions

CKD not on dialysis dosing: Approved if doses are equivalent to less than 60,000 units total per month.< 60,000 units/month

Dosing change recorded in policy history

Hemoglobin threshold for patients currently receiving ESA: Hemoglobin level criterion changed to <12.0 g/dL and age-based delineation removed.

Requests for epoetin alfa for indications listed under Conditions Not Recommended for Approval are not recommended for coverage. These include: anemia in cancer patients not receiving cancer chemotherapy; anemia associated with acute myeloid leukemia (AML), chronic myelogenous leukemia (CML) or other myeloid/erythroid cancers; anemia associated with radiotherapy alone; use to enhance athletic performance; treatment of acute blood loss; and administration to non‑anemic preoperative patients (Hb > 13.0 g/dL). Coverage is also not recommended for other circumstances not specified in the Recommended Authorization criteria.

This policy does not apply to providers or members in Palmetto GBA jurisdictions J‑J and J‑M. Jurisdictions affected include Alabama, Georgia, Tennessee, North Carolina, South Carolina, Virginia, and West Virginia; these states require separate jurisdiction‑specific guidance and thus are excluded from this Medicare Advantage medical policy.

Use of epoetin alfa for indications lacking evidence of effectiveness, supported only by preliminary data, or associated with potential safety concerns (see Conditions Not Recommended for Approval) is not recommended as medically necessary and therefore not supported for coverage under this policy.

The presence of a specific HCPCS or ICD‑10 code in the chart or in companion LCD/Article lists is not by itself sufficient to approve coverage. Likewise, absence of a particular code does not, by itself, exclude a diagnosis from consideration. Coverage decisions require the full set of clinical criteria and documentation described in this policy.

Billing, Codes, and Clinical Thresholds

Billing/Coding references (companion lists referenced)mixed

not listed

Policy references that companion articles/LCDs include specific HCPCS and ICD‑10 codes for billing/coding but does not enumerate them in this section.

Hemoglobin thresholds

Initiation thresholdInitiate therapy commonly at hemoglobin ≤10.0 g/dL

Titration for dialysis patientsReduce or interrupt dose if hemoglobin approaches or exceeds 11.0 g/dL

Withhold recommendationWithhold epoetin alfa if hemoglobin exceeds 12.0 g/dL in some contexts

Dose and unit limits

Per‑dose Units/kg limitsExamples include each dose <300 Units/kg (common) with variations up to <400 or <900 Units/kg depending on age/indication

Frequency limitsEach dose generally given no more frequently than 3 times per week; some regimens restrict to once weekly or no more frequently than twice weekly depending on indication

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Prior Authorization for ESA therapy

Prior authorization is required for medical benefit coverage of erythropoiesis‑stimulating agent (ESA) therapy for indications other than CKD on dialysis. Requests should confirm the clinical indication and that dosing falls within the policy limits (e.g., monthly equivalent dosing < 60,000 units for CKD not on dialysis or per-indication dosing limits). Approvals are issued for the duration specified in the Criteria (e.g., 3 years for CKD on dialysis, 1 year for CKD not on dialysis, 6 months initial for chemotherapy-induced anemia).

Prior authorization must document indication, hemoglobin/hematocrit values, and dosing consistent with the policy dosing limits.
Duration of initial approvals varies by indication (examples: CKD on dialysis — 3 years; CKD not on dialysis — 1 year; chemotherapy-induced anemia — initial approval limited to 6 months).

Denial Risk

Excluded Indications

Certain clinical indications are explicitly not recommended for approval. Requests for these indications should be denied unless robust new evidence justifies coverage and is documented in the request.

Background and Scope

Epoetin alfa is an erythropoiesis‑stimulating agent (ESA) indicated for treatment of anemia from multiple causes including chronic kidney disease (on dialysis and not on dialysis), anemia due to cancer chemotherapy, anemia in patients with HIV receiving zidovudine, and to reduce need for allogeneic red blood cell transfusions in selected perioperative patients. Therapy is titrated to hemoglobin response using the lowest effective dose and clinicians should avoid exceeding recommended hemoglobin thresholds due to established safety concerns.

Definitions and Key Terms

ESA (erythropoiesis‑stimulating agent)

DefinitionErythropoiesis‑stimulating agents (ESAs) — drugs that stimulate red blood cell production, e.g., epoetin alfa products (Epogen, Procrit, Retacrit), darbepoetin alfa, and methoxy polyethylene glycol‑epoetin beta

Primary indicationsUsed to treat anemia from CKD (on and not on dialysis), chemotherapy, zidovudine in HIV, and to reduce perioperative RBC transfusions in selected patients

Therapeutic principleTherapy is titrated to hemoglobin response using the lowest effective dose to avoid transfusions and minimize safety risks

Iron adequacy

DefinitionIron adequacy — presence of sufficient iron stores or current iron therapy (measured with ferritin, transferrin saturation or other iron studies) to support response to ESA

Authorization expectation

Policy Summary

PayerEmblemHealth

PolicyErythropoiesis‑Stimulating Agents — Epoetin Alfa Products (Medical Utilization Management)

Policy CodePolicy N/A

Change TypeClinical revisions and dosing/threshold updates

Effective DateN/A

Next Review DateN/A

SourceLink

On This Page

Documentation Required

Required Documentation

Prior authorization requests must include clinical documentation that the patient meets the specific indication criteria. Include laboratory values, current therapies, and prescriber assessment of iron status where applicable.

Diagnosis and reason for ESA therapy (specific indication matching policy criteria).
Recent hemoglobin (and hematocrit if relevant) values with dates.
Documentation of iron status: current iron therapy or prescriber assessment of adequate iron stores.
If receiving zidovudine or chemotherapy, documentation that the patient is on the listed therapy and whether chemotherapy is considered myelosuppressive and non‑curative (for cancer-related indications).
Prior and current ESA dosing and frequency.
For continuation requests, evidence that patient continues to meet the original approval criteria.

Prior Authorization

Initial therapy limits

Initial therapy approvals have indication‑specific time limits. Requests for durations beyond the initial approval must demonstrate continued medical necessity per the policy's continuation criteria.

Chemotherapy‑induced anemia — initial approval limited to 6 months; documentation must include iron status (receiving iron therapy or adequate iron stores) and that chemotherapy is myelosuppressive and considered non‑curative per prescriber.
CKD on dialysis — typical approval duration is 3 years per policy.
CKD not on dialysis and other indications (e.g., MDS) — initial approvals commonly 1 year; dosing must be within the policy monthly equivalent limits (e.g., < 60,000 units per month where specified).